This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Diabetic Retinopathy  • Macular Disorders  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

It’s Time for Clinical Trials

Arch Ophthalmol. 2005;123:258-259.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Our goal as ophthalmologists is to preserve and improve the vision of our patients. As part of this mission, we counsel our patients regarding the risks and benefits of various therapies. New treatments that have limited or unproven therapeutic value create an awkward position for ophthalmologists.

In the treatment of posterior segment diseases, randomized prospective multicenter clinical trials using treatment such as argon laser photocoagulation or pars plana vitrectomy have established the standard of care for patients with retinal vascular diseases. In the first major clinical trial in ophthalmology, the Diabetic Retinopathy Study¹ showed clear evidence that panretinal photocoagulation reduced rates of severe visual loss in treated eyes compared with an untreated control group. Additional randomized prospective clinical trials on photocoagulation include the Early Treatment Diabetic Retinopathy Study,² the Branch Vein Occlusion Study,³ and the Central Vein Occlusion Study.⁴ These carefully conducted and very important randomized clinical trials reported the . . . [Full Text of this Article]

AUTHOR INFORMATION
Harry W. Flynn, Jr, MD; Ingrid U. Scott, MD, MPH

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

New Therapy for Central Retinal Vein Occlusion: Are Intravitreal Steroids a Possible Answer?
Mark S. Blumenkranz
Arch Ophthalmol. 2005;123(2):259-261.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5
The SCORE Study Research Group
Arch Ophthalmol 2009;127:1101-1114.
ABSTRACT | FULL TEXT  

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6
The SCORE Study Research Group
Arch Ophthalmol 2009;127:1115-1128.
ABSTRACT | FULL TEXT  

Dexamethasone Inhibits High Glucose-, TNF-{alpha}-, and IL-1{beta}-Induced Secretion of Inflammatory and Angiogenic Mediators from Retinal Microvascular Pericytes
Nehme and Edelman
IOVS 2008;49:2030-2038.
ABSTRACT | FULL TEXT  

Long-term Retinal Toxicity of Intravitreal Commercially Available Preserved Triamcinolone Acetonide (Kenalog) in Rabbit Eyes
Albini et al.
IOVS 2007;48:390-395.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone therapy for diabetic macular oedema
Vernon
Br J Ophthalmol 2005;89:931-933.
FULL TEXT